AI Summary
Generated by AI for informational purposes only
This medicine is used to treat bone problems like osteoporosis in women after menopause. It works by preventing bone loss and helping to keep bones strong. Its use is generally not recommended during pregnancy or breastfeeding.
Indications
Salmon Calcitonin is indicated in Active Paget's disease in patients who do not respond to alternative treatments or for whom such treatments are not suitable; Hypercalcaemia.
Composition
Each ml Salmon Calcitonin injection contains-
50 or 100 I.U. salcatonin (present as Polyacetate polyhydrate)
Sodium acetate 0.2%
Glacial acetic acid 0.2%
Sodium chloride 0.75%
Salmon Calcitonin contains 32 amino-acids in linear sequence with a disulphide bridge at position 1 and 7 and a molecular weight of 3431.9 (free peptide). Salcatonin is a white or grey-tinged white amorphous powder. It is very soluble in water and very slightly soluble in alcohol.
Description
Naturally-occurring calcitonin is synthesised by parafollicular cells in the thyroid gland of mammals and the ultimobranchial gland of birds and fish. The potency of salmon calcitonin is standardised according to its ability to lower plasma calcium levels of rats as compared to the International Reference standard.
Pharmacology
Calcitonin is a polypeptide hormone produced by the ultimobranchial gland in non-mammalian vertebrates or by the mammalian thyroid parafollicular cells. It inhibits osteoclastic bone resorption and reduces bone turnover. It decreases tubular reabsorption and promotes renal excretion of Ca, Cl, Na, Mg, K and phosphate.
Dosage & Administration
Important: Do not take any medication without a doctor's prescription. Self-medication can be dangerous.
Intravenous (Adult)-
Emergency treatment of hypercalcaemia: Up to 10 u/kg in 500 mL of sodium chloride 0.9% by slow IV infusion over at least 6 hr.
Parenteral (Adult)-
Adjunct in hypercalcaemia: SC/IM: 4 u/kg 12 hrly, may increase after 1-2 days to 8 u/kg 12 hrly to max 8 u/kg 6 hrly after 2 days. Alternatively, 100 u every 6-8 hr, increased after 1-2 days to max 400 u every 6-8 hr.
Paget's disease of bone: SC/IM: 50 u 3 times wkly to 100 u/day.
Concurrent use wth cardiac glycosides (e.g. digitalis) or Ca-channel blockers requires dosage adjustments of these drugs. May decrease serum concentration of lithium.
Contraindications
Hypersensitivity. Patients with hypocalcaemia.
Side Effects
GI disturbances, dizziness, flushing, tingling of the hands, unpleasant taste, skin rash, abdominal pain, urinary frequency, tremor, inj site inflammation. Rarely, diabetogenic effect.
Pregnancy & Lactation
Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Precautions & Warnings
Skin test should be done before initiating therapy. Heart failure; renal impairment. Pregnancy, lactation, childn.
Use in Special Populations
Renal Impairment: Dosage adjustment needed.
Overdose Effects
Symptoms: Flushing, nausea, vomiting and dizziness. Management: Symptomatic and supportive treatment.
Storage Conditions
Store between 2-8° C.
The information provided on this page is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Always consult a qualified healthcare professional before starting, stopping, or changing any medication.
All brands listed might have copyright or trademark of their respective owners. Listed information may not be up-to-date or accurate. We do not guarantee the availability, quality, price or safety of any medication. Use at your own risk.
